Gilead Sciences, Inc. (GILD)
GILD moved a median of -0.00% 30 minutes after news, and +0.05% by the close. How GILD actually reacts to news — the realized, point-in-time move the market made, measured across 677 labeled events over the last three years with zero look-ahead.
GILD’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.03% | 52% | 672 |
| 30-min | -0.00% | 50% | 672 |
| 60-min | +0.03% | 51% | 673 |
| to close | +0.05% | 52% | 670 |
| Middle 50% of GILD reactions | -0.47% to +0.54% |
|---|---|
| Median reaction (30-min) | -0.00% |
| Measured reactions | 677 |
Half of all Gilead Sciences, Inc. news events land between -0.47% and +0.54% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How GILD reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 48 | -0.05% | 44% | -0.22% |
| Analyst downgrades | 13 | +0.04% | 54% | -0.07% |
| Coverage initiations | 27 | -0.42% | 44% | +0.09% |
| Rating reiterations | 151 | +0.01% | 50% | +0.19% |
| Price-target raises | 96 | -0.09% | 44% | +0.23% |
| Price-target cuts | 31 | +0.01% | 52% | -0.18% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how GILD ranks against every other measured name →
That’s how GILD usually reacts — get an email when it moves on news →Email me when GILD moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to GILD's baseline. Nothing else.
Recent GILD events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention | Press release | Business Wire | +0.18% | +0.75% | |
| Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean | Press release | Business Wire | +0.00% | +1.24% | |
| Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines | Press release | Business Wire | -0.10% | +0.35% | |
| U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens | Press release | Business Wire | -0.88% | -2.54% | |
| Form N-PX GILEAD SCIENCES, INC. For: Jun 30 | SEC filing · Form N-PX | SEC EDGAR | +0.02% | +1.06% | |
| Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences | Press release | Business Wire | +0.02% | +1.06% | |
| European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status | Press release | Business Wire | -0.80% | +0.35% | |
| Form 10-Q GILEAD SCIENCES, INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.64% | +0.84% | |
| Form S-3ASR GILEAD SCIENCES, INC. | SEC filing · Form S-3ASR | SEC EDGAR | -0.64% | +0.84% | |
| Form 8-K GILEAD SCIENCES, INC. For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | +0.41% | -3.12% | |
| Gilead Sciences Announces Second Quarter 2026 Financial Results | Press release | Business Wire | +0.41% | -3.12% | |
| Form 13F-HR GILEAD SCIENCES, INC. For: Jun 30 | SEC filing · Form 13F-HR | SEC EDGAR | -0.88% | +3.13% | |
| CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer | Press release | Business Wire | -0.50% | -1.24% | |
| Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 | Press release | Business Wire | -0.51% | -1.13% | |
| Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure | Press release | Business Wire | +0.19% | -0.96% | |
| Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy | Press release | Business Wire | +0.58% | -0.57% | |
| U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer | Press release | Business Wire | +0.13% | -1.13% | |
| European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors | Press release | Business Wire | -1.22% | -1.25% | |
| U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention | Press release | Business Wire | -0.27% | +1.25% | |
| Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief | Press release | Business Wire | -0.17% | -0.43% | |
| National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership | Press release | Business Wire | +1.07% | +3.35% | |
| Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment | Press release | Business Wire | -2.03% | -2.56% | |
| Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa | Press release | Business Wire | +0.03% | -0.95% | |
| Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline | Press release | Business Wire | +0.03% | -0.95% | |
| Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC) | Press release | Business Wire | +1.47% | -0.64% | |
| Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar) | Press release | Business Wire | -0.17% | -0.10% | |
| FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV) | Press release | Business Wire | -0.16% | +0.40% | |
| Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors | Press release | Business Wire | +0.86% | +2.12% | |
| Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease | Press release | Business Wire | -0.23% | +0.26% | |
| Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio | Press release | Business Wire | -0.60% | -0.12% | |
| New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology | Press release | Business Wire | +0.86% | +2.12% | |
| Form 8-K GILEAD SCIENCES, INC. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -0.23% | +0.26% | |
| Gilead Prices $3 Billion of Senior Unsecured Notes | Press release | Business Wire | -0.68% | -2.03% | |
| Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026 | Press release | Business Wire | -0.84% | -0.42% | |
| Form 13F-HR GILEAD SCIENCES, INC. For: Mar 31 | SEC filing · Form 13F-HR | SEC EDGAR | +1.14% | +1.94% | |
| Form 10-Q GILEAD SCIENCES, INC. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.24% | +1.02% | |
| Form 8-K GILEAD SCIENCES, INC. For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +1.24% | +1.02% | |
| Form S-8 GILEAD SCIENCES, INC. | SEC filing · Form S-8 | SEC EDGAR | +1.24% | +1.02% | |
| Gilead Sciences Announces First Quarter Financial Results | Press release | Business Wire | +1.24% | +1.02% | |
| Form 8-K GILEAD SCIENCES, INC. For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | -0.04% | +0.48% | |
| Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences | Press release | Business Wire | +0.03% | +1.27% | |
| U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir | Press release | Business Wire | +0.68% | +0.27% | |
| Form 8-K GILEAD SCIENCES, INC. For: Apr 28 | SEC filing · Form 8-K | SEC EDGAR | -1.19% | -0.93% | |
| Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel | Press release | Business Wire | -1.19% | -0.93% | |
| Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026 | Press release | Business Wire | +0.10% | -0.28% | |
| Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer | Press release | Business Wire | +0.09% | -0.94% | |
| PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access | Press release | Business Wire | -0.06% | +0.09% | |
| Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline | Press release | Business Wire | -0.79% | +0.35% | |
| Gilead Extends Tender Offer to Acquire Arcellx | Press release | Business Wire | +0.33% | +0.09% | |
| Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases | Press release | Business Wire | +0.37% | +0.96% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the GILD section they belong to.
Where else GILD is measured.
GILD earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Marinus Pharmaceuticals, Inc. (MRNS) | 687 | 0.00% | 50% |
| PTC Therapeutics, Inc. (PTCT) | 686 | +0.01% | 50% |
| ONCOMED PHARMACEUTICALS (OMED) | 677 | -0.20% | 44% |
| ARATANA THERAPEUTICS (PETX) | 677 | 0.00% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Gilead Sciences, Inc.'s median reaction calculated?
Every labeled GILD news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 677 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of GILD's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does GILD's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.